Schiergens Tobias S, Rentsch Markus, Kasparek Michael S, Frenes Katharina, Jauch Karl-Walter, Thasler Wolfgang E
Department of General, Visceral, Transplantation, Vascular, and Thoracic Surgery, University of Munich, Campus Grosshadern, Munich, Germany.
Dis Colon Rectum. 2015 Jan;58(1):74-82. doi: 10.1097/DCR.0000000000000233.
Perioperative allogeneic red blood cell transfusion has been conclusively shown to be associated with adverse oncologic outcomes after resection of nonmetastatic colorectal adenocarcinoma.
The aim of the study was to identify risk factors for a perioperative transfusion and to assess the effects of transfusion on survival after curative-intended resection of hepatic metastases in patients featuring stage IV colorectal cancer.
This was an observational study with a retrospective analysis of a prospective data collection.
The study was conducted at a tertiary care center.
A total of 292 patients undergoing curative-intended liver resection for colorectal liver metastases were included in the study.
Univariate and multivariate analyses were performed identifying factors influencing transfusion, recurrence-free survival, and overall survival.
A total of 106 patients (36%) received allogeneic red blood cells. Female sex (p = 0.00004), preoperative anemia (p = 0.001), major intraoperative blood loss (p < 0.00001), and major postoperative complications (p = 0.02) were independently associated with the necessity of transfusion. Median recurrence-free and overall survival were 58 months. Allogeneic red blood cell transfusion was significantly associated with reduced recurrence-free survival (32 vs 72 months; p = 0.008). It was reduced further by administration of >2 units (27 months; p = 0.02). Overall survival was not significantly influenced by transfusion (48 vs 63 months; p = 0.08). When multivariately adjusted for major intraoperative blood loss and factors univariately associated, namely comorbidities, tumor load, and positive resection margins, transfusion was an independent predictor for reduced recurrence-free survival (p = 0.03).
These include the retrospective and observational design, as well as the impossibility to prove causality of the association between transfusion and poor outcome.
In patients undergoing liver resection for colorectal liver metastases, perioperative transfusion is independently associated with earlier disease recurrence. This emphasizes appropriate blood management measures, including the conservative correction of preoperative anemia, the use of low transfusion triggers, and the minimization of intraoperative blood loss.
围手术期异体红细胞输血已被确凿证明与非转移性结直肠癌切除术后不良肿瘤学结局相关。
本研究旨在确定围手术期输血的危险因素,并评估输血对IV期结直肠癌患者肝转移灶根治性切除术后生存的影响。
这是一项观察性研究,对前瞻性数据收集进行回顾性分析。
该研究在一家三级医疗中心进行。
共有292例因结直肠癌肝转移接受根治性肝切除的患者纳入本研究。
进行单因素和多因素分析,以确定影响输血、无复发生存期和总生存期的因素。
共有106例患者(36%)接受了异体红细胞输血。女性(p = 0.00004)、术前贫血(p = 0.001)、术中大量失血(p < 0.00001)和术后严重并发症(p = 0.02)与输血必要性独立相关。无复发生存期和总生存期的中位数为58个月。异体红细胞输血与无复发生存期缩短显著相关(32个月对72个月;p = 0.008)。输注超过2单位血液时无复发生存期进一步缩短(27个月;p = 0.02)。输血对总生存期无显著影响(48个月对63个月;p = 0.08)。在对术中大量失血以及单因素相关因素(即合并症、肿瘤负荷和切缘阳性)进行多因素校正后,输血是无复发生存期缩短的独立预测因素(p = 0.03)。
包括回顾性和观察性设计,以及无法证明输血与不良结局之间关联的因果关系。
在因结直肠癌肝转移接受肝切除的患者中,围手术期输血与疾病早期复发独立相关。这强调了采取适当的血液管理措施,包括保守纠正术前贫血、采用低输血阈值以及尽量减少术中失血。